Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis

Clinical Kidney Journal

Volumn 5, Issue 1, 2012, Pages 34-36

  Kim, Jon Jin ^a   Waller, Simon C ^a   Reid, Christopher J ^a  

^a EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

atypical haemolytic uraemic syndrome; dialysis; eculizumab; plasma exchange

Indexed keywords

ALBUMIN; COMPLEMENT FACTOR H; CREATININE; ECULIZUMAB; HEMOGLOBIN; MENINGOCOCCUS VACCINE; NITROPRUSSIDE SODIUM; OCTAPLAS; UREA;

ARTICLE; CASE REPORT; CHILD; CONTINUOUS HEMOFILTRATION; CREATININE BLOOD LEVEL; ERYTHROCYTE TRANSFUSION; EXON; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC SCREENING; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; HYPERVOLEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; OLIGURIA; PALLOR; PERITONEAL DIALYSIS; PLASMA TRANSFUSION; PLASMAPHERESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SKIN BRUISING; THROMBOCYTE COUNT; TREATMENT DURATION; UREA BLOOD LEVEL; URINE COLOR;

EID: 84898865896     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ndtplus/sfr174     Document Type: Article

References (11)

1. Ariceta G, Besbas N, Johnson S et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009; 24: 687-696
2. Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol 2011; 26: 41-57
3. Kim JJ, Goodship THJ, Tizard EJ et al. Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations. Pediatr Nephrol 2011; 26: 2073-2076
4. Pru fer F, Scheiring J, Sautter S et al. Terminal complement complex (C5b-9) in children with recurrent haemolytic uremic syndrome. Semin Thromb Hemost 2006; 32: 121-127
5. Gruppo RA, Rother RP. Eculizumab for congenital atypical haemolytic-uremic syndrome. N Engl J Med 2009; 360: 544-546
6. Lapeyraque AL, Fremeaux-Bacchi V, Robitaille P. Efficacy of eculizumab in a patient with factor-H-Associated atypical hemolytic uremic syndrome. Pediatr Nephrol 2011; 26: 621-624
7. Tschumi S, Gugger M, Bucher BS et al. Eculizumab in atypical hemolytic uremic syndrome: long-Term clinical course and histological findings. Pediatr Nephrol 2011; 26: 2085-2088
8. Mache CJ, Acham-Roschitz B, Fremeaux-Bacchi V et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 1312-1316
9. Roth A, Hock C, Konik A et al. Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena. Int J Hematol 2011; 93: 704-714
10. Bouts A, Monnens L, Davin JC et al. Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy. Pediatr Nephrol 2011; doi:10.1007/s00467-011-1929-3
11. Haller W, Milford DV, Goodship TH et al. Successful isolated liver transplantation in a child with atypical haemolytic uremic syndrome and a mutation in complement factor H. Am J Transplant 2010; 10: 2142-2147